Literature DB >> 32703775

Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children.

Kendra K Radtke1, Jennifer E Hibma1, Anneke C Hesseling2, Rada M Savic1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 32703775      PMCID： PMC7870317          DOI： 10.1183/13993003.01756-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  10 in total

1.  Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.

Authors:  M Elsa Villarino; Nigel A Scott; Stephen E Weis; Marc Weiner; Marcus B Conde; Brenda Jones; Sharon Nachman; Ricardo Oliveira; Ruth N Moro; Nong Shang; Stefan V Goldberg; Timothy R Sterling
Journal:  JAMA Pediatr       Date:  2015-03       Impact factor: 16.193

2.  Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection.

Authors:  Marc Weiner; Radojka M Savic; William R Mac Kenzie; Diane Wing; Charles A Peloquin; Melissa Engle; Erin Bliven; Thomas J Prihoda; Jonathan A L Gelfond; Nigel A Scott; Susan M Abdel-Rahman; Gregory L Kearns; William J Burman; Timothy R Sterling; M Elsa Villarino
Journal:  J Pediatric Infect Dis Soc       Date:  2014-01-16       Impact factor: 3.164

3.  Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study.

Authors:  Kendra K Radtke; Kelly E Dooley; Peter J Dodd; Anthony J Garcia-Prats; Lindsay McKenna; Anneke C Hesseling; Radojka M Savic
Journal:  Lancet Child Adolesc Health       Date:  2019-07-16

4.  Three months of rifapentine and isoniazid for latent tuberculosis infection.

Authors:  Timothy R Sterling; M Elsa Villarino; Andrey S Borisov; Nong Shang; Fred Gordin; Erin Bliven-Sizemore; Judith Hackman; Carol Dukes Hamilton; Dick Menzies; Amy Kerrigan; Stephen E Weis; Marc Weiner; Diane Wing; Marcus B Conde; Lorna Bozeman; C Robert Horsburgh; Richard E Chaisson
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

5.  Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.

Authors:  Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

Review 6.  The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era.

Authors:  B J Marais; R P Gie; H S Schaaf; A C Hesseling; C C Obihara; J J Starke; D A Enarson; P R Donald; N Beyers
Journal:  Int J Tuberc Lung Dis       Date:  2004-04       Impact factor: 2.373

7.  Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.

Authors:  Jennifer E Hibma; Kendra K Radtke; Susan E Dorman; Amina Jindani; Kelly E Dooley; Marc Weiner; Helen M McIlleron; Radojka M Savic
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

8.  The global burden of tuberculosis mortality in children: a mathematical modelling study.

Authors:  Peter J Dodd; Courtney M Yuen; Charalambos Sismanidis; James A Seddon; Helen E Jenkins
Journal:  Lancet Glob Health       Date:  2017-09       Impact factor: 26.763

9.  Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.

Authors:  Benjamin Guiastrennec; Geetha Ramachandran; Mats O Karlsson; A K Hemanth Kumar; Perumal Kannabiran Bhavani; N Poorana Gangadevi; Soumya Swaminathan; Amita Gupta; Kelly E Dooley; Radojka M Savic
Journal:  Clin Pharmacol Ther       Date:  2018-02-02       Impact factor: 6.875

10.  Prevention of tuberculosis in household members: estimates of children eligible for treatment.

Authors:  Yohhei Hamada; Philippe Glaziou; Charalambos Sismanidis; Haileyesus Getahun
Journal:  Bull World Health Organ       Date:  2019-05-28       Impact factor: 9.408
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.